Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1

Genome Medicine

Volumn 5, Issue 1, 2013, Pages

  Nies, Anne T ^a   Niemi, Mikko ^b   Burk, Oliver ^a   Winter, Stefan ^a   Zanger, Ulrich M ^a   Stieger, Bruno ^c   Schwab, Matthias ^a   Schaeffeler, Elke ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CARRIER PROTEINS AND BINDING PROTEINS; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 4; SLCO1B3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; GENE EXPRESSION; GENETICS; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84872149285     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm405     Document Type: Article

References (80)

1. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004, 447:653-665. 10.1007/s00424-003-1168-y, 14579113.
2. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005, 78:260-277. 10.1016/j.clpt.2005.05.011, 16153397.
3. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236. 10.1038/nrd3028, 3326076, 20190787.
4. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011, 63:157-181. 10.1124/pr.110.002857, 21245207.
5. Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 2008, 4:545-568. 10.1517/17425255.4.5.545, 18484914.
6. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012, 122:519-528. 10.1172/JCI59526, 3266790, 22232210.
7. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006, 16:873-879. 10.1097/01.fpc.0000230416.82349.90, 17108811.
8. Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE, Relling MV. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012, 22:1-8. 10.1101/gr.129668.111, 3246196, 22147369.
9. SEARCH Collaborative Group SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008, 359:789-799. SEARCH Collaborative Group.
10. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005, 15:513-522. 10.1097/01.fpc.0000170913.73780.5f, 15970799.
11. Clarke JD, Cherrington NJ. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol 2012, 8:349-360. 10.1517/17425255.2012.656087, 22280100.
12. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009, 51:565-580. 10.1016/j.jhep.2009.05.012, 19595470.
13. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009, 50:1227-1240. 10.1002/hep.23103, 19591196.
14. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 2001, 276:37206-37214. 10.1074/jbc.M103988200, 11483603.
15. Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002, 122:1954-1966. 10.1053/gast.2002.33583, 12055601.
16. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004, 40:212-218. 10.1016/j.jhep.2003.10.008, 14739090.
17. Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, Mizutamari H, Mikkaichi T, Oikawa M, Rikiyama T, Katayose Y, Unno M. Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol 2006, 41:369-377. 10.1007/s00535-006-1784-3, 16741617.
18. Maeda T, Hirayama M, Higashi R, Sato M, Tamai I. Characterization of human OATP2B1 (SLCO2B1) gene promoter regulation. Pharm Res 2006, 23:513-520. 10.1007/s11095-006-9572-6, 16489487.
19. Jigorel E, Le VM, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006, 34:1756-1763. 10.1124/dmd.106.010033, 16837569.
20. Furihata T, Satoh T, Yamamoto N, Kobayashi K, Chiba K. Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm Res 2007, 24:2327-2332. 10.1007/s11095-007-9458-2, 17932728.
21. Meyer zu Schwabedissen HE, Bottcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB. Liver X receptor alpha and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 2010, 52:1797-1807. 10.1002/hep.23876, 20827719.
22. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006, 44:62-74.
23. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010, 1:129. 3171976, 21918647.
24. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007, 82:726-733. 10.1038/sj.clpt.6100220, 17473846.
25. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008, 84:457-461. 10.1038/clpt.2008.25, 19238649.
26. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009, 86:197-203. 10.1038/clpt.2009.79, 19474787.
27. Schröder A, Klein K, Winter S, Schwab M, Bonin M, Zell A, Zanger UM. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J 2011, 13:12-20. 3564008, 22006096.
28. Cui Y, König J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003, 83:527-538.
29. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001, 120:525-533. 10.1053/gast.2001.21176, 11159893.
30. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 2008, 584:57-65. 10.1016/j.ejphar.2008.01.042, 2376123, 18321482.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265. 10.1093/bioinformatics/bth457, 15297300.
32. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005, 76:887-893. 10.1086/429864, 1199378, 15789306.
33. The R project for statistical computing. http://www.r-project.org
34. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979, 6:65-70.
35. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616. 10.1016/j.jacc.2009.04.053, 3417133, 19833260.
36. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2011, 12:237.
37. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002, 302:804-813. 10.1124/jpet.302.2.804, 12130747.
38. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004, 14:749-757. 10.1097/00008571-200411000-00006, 15564882.
39. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004, 75:415-421. 10.1016/j.clpt.2003.12.016, 15116054.
40. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006, 79:427-439. 10.1016/j.clpt.2006.01.011, 16678545.
41. Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 2008, 18:937-942. 10.1097/FPC.0b013e32830d733e, 18854776.
42. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011, 89:210-216. 10.1038/clpt.2010.255, 3353487, 21178985.
43. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RD. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A > G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011, 12:5815-5827. 10.3390/ijms12095815, 3189752, 22016628.
44. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005, 78:330-341. 10.1016/j.clpt.2005.06.013, 16198652.
45. Bartoszewski RA, Jablonsky M, Bartoszewska S, Stevenson L, Dai Q, Kappes J, Collawn JF, Bebok Z. A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein. J Biol Chem 2010, 285:28741-28748. 10.1074/jbc.M110.154575, 2937902, 20628052.
46. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 2011, 41:24-34. 10.3109/00498254.2010.523736, 20946088.
47. Pomari E, Nardi A, Fiore C, Celeghin A, Colombo L, Valle LD. Transcriptional control of human organic anion transporting polypeptide 2B1 gene. J Steroid Biochem Mol Biol 2009, 115:146-152. 10.1016/j.jsbmb.2009.04.003, 19383542.
48. Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 2005, 56:790-792. 10.1093/jac/dki314, 16143711.
49. Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002, 20:4303-4312. 10.1200/JCO.2002.03.123, 12409328.
50. Kusuhara H, Sugiyama Y. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab Rev 2010, 42:539-550. 10.3109/03602530903491824, 20175646.
51. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003, 38:978-988.
52. Le Vee M, Jouan E, Stieger B, Lecureur V, Fardel O. Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochem Pharmacol 2011, 82:304-311. 10.1016/j.bcp.2011.04.017, 21570956.
53. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011, 3:82. 10.1186/gm298, 3334547, 22196450.
54. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012, 55:821-832. 10.1002/hep.24682, 21932399.
55. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001, 11:399-415. 10.1097/00008571-200107000-00004, 11470993.
56. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000, 278:G156-G164.
57. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006, 130:1793-1806. 10.1053/j.gastro.2006.02.034, 16697742.
58. Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 2008, 376:449-461. 10.1007/s00210-007-0219-x, 18157518.
59. Kopplow K, Letschert K, König J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005, 68:1031-1038. 10.1124/mol.105.014605, 16046661.
60. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation uptake transporters (OCTs). PLoS ONE 2011, 6:e22163. 10.1371/journal.pone.0022163, 3136501, 21779389.
61. Locker J, Ghosh D, Luc PV, Zheng J. Definition and prediction of the full range of transcription factor binding sites--the hepatocyte nuclear factor 1 dimeric site. Nucleic Acids Res 2002, 30:3809-3817. 10.1093/nar/gkf484, 137408, 12202766.
62. Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, Burk O. Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 2007, 35:946-954. 10.1124/dmd.106.013565, 17344340.
63. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, Schwab M, Eichelbaum M, Zanger UM. A natural CYP2B6 TATA box polymorphism (-82T-- > C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 2005, 67:1772-1782. 10.1124/mol.104.008086, 15722458.
64. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001, 276:14581-14587. 10.1074/jbc.M010173200, 11297522.
65. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249. 10.1038/nmeth0410-248, 2855889, 20354512.
66. PolyPhen-2. http://genetics.bwh.harvard.edu/pph2
67. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081. 10.1038/nprot.2009.86, 19561590.
68. SIFT. http://sift.jcvi.org
69. Ferrer-Costa C, Orozco M, de lC X. Sequence-based prediction of pathological mutations. Proteins 2004, 57:811-819. 10.1002/prot.20252, 15390262.
70. PMut. http://mmb.pcb.ub.es/PMut
71. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006, 7:166. 10.1186/1471-2105-7-166, 1435944, 16551372.
72. SNPs3D. http://www.snps3d.org
73. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999, 288:911-940. 10.1006/jmbi.1999.2700, 10329189.
74. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003, 31:3406-3415. 10.1093/nar/gkg595, 169194, 12824337.
75. MFold. http://mfold.rit.albany.edu/?q=mfold
76. Tietz NW. Clinical Guide to Laboratory Tests 1995, Philadelphia: WB Saunders.
77. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11:272-276.
78. Ho WF, Koo SH, Yee JY, Lee EJ. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet 2008, 23:476-482. 10.2133/dmpk.23.476, 19122343.
79. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M. Highly multiplexed genotyping of thiopurine S-methyltransferase variants using MALDI-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 2008, 54:1637-1647. 10.1373/clinchem.2008.103457, 18687736.
80. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001, 276:35669-35675. 10.1074/jbc.M103792200, 11477075.